Bolt Biotherapeutics
BOLT
61 hedge funds and large institutions have $54.8M invested in Bolt Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 18 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.31% less ownership
Funds ownership: 3.89% → 3.58% (-0.31%)
6% less funds holding
Funds holding: 65 → 61 (-4)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
26% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 19
35% less capital invested
Capital invested by funds: $84.8M → $54.8M (-$30M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$1.45M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$874K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$535K |
| 4 |
Renaissance Technologies
New York
|
+$482K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$388K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ESCM
Echo Street Capital Management
New York
|
-$5.49M |
| 2 |
Holocene Advisors
New York
|
-$3.19M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.36M |
| 4 |
BlackRock
New York
|
-$2.26M |
| 5 |
AC
Armistice Capital
New York
|
-$1.1M |
BOLT Hedge Fund Activity: Q2 2022 in Review
61 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q2 2022, worth a combined $54.8M — down 35% from $84.8M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of BOLT and 16 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 14 added.
The largest buyer was Newtyn Management, opening a new position worth an estimated $1.45M. The largest seller was Echo Street Capital Management, exiting entirely with an estimated $5.49M sold.
- 61 institutional investors held Bolt Biotherapeutics (BOLT) as of Q2 2022, down from 65 in Q1 2022.
- Funds reported $54.8M of Bolt Biotherapeutics stock for Q2 2022, down 35% quarter-over-quarter.
- 16 funds opened new Bolt Biotherapeutics positions in Q2 2022 and 18 closed out, a net change of -2 holders.
- The largest Bolt Biotherapeutics buyer in Q2 2022 was Newtyn Management, an estimated $1.45M added.
- The largest Bolt Biotherapeutics seller in Q2 2022 was Echo Street Capital Management, an estimated $5.49M sold.
Based on aggregated 13F filings for Q2 2022.